Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities

Leukemia

Volumn 16, Issue 11, 2002, Pages 2177-2184

  Pedersen Bjergaard, J ^a   Christiansen, D H ^a   Andersen, M K ^a   Skovby, F ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Acute myeloid leukemia; Alkylating agents; Chromosome abnormalities; Epidemiology; Myelodysplasia; Related leukemia; Therapy; Topoisomerase II inhibitors

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; MITOXANTRONE; PIPERAZINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER RISK; CHROMOSOME 5Q; CLINICAL RESEARCH; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; EPIDEMIOLOGY; GENE MUTATION; GENETIC DISORDER; GENETIC RECOMBINATION; HUMAN; MALIGNANT TRANSFORMATION; MONOSOMY 7; MOUSE; MYELODYSPLASIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS;

EID: 0036848258     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402764     Document Type: Article

References (116)

1. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. Report of four cases possibly related to melphalan. N Engl J Med 1970; 283: 1421-1125.
2. Reimer RR, Hoover R, Fraumeni JF Jr, Young RC. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med 1977; 297: 177-181.
3. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979; 301: 743-748.
4. Pedersen-Bjergaard J, Nissen NI, Søorensen HM, Hou-Jensen K, Larsen, MS, Ernst P, Ersbol J, Knudtzon S, Rose C. Acute nonlymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with treosulfan (=dihydroxybusulfan). Cancer 1980; 45: 19-29.
5. Greene MH, Boice JD Jr, Greer BE, Blessing JA, Dembo AJ. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer. N Engl J Med 1982; 307: 1416-1421.
6. Pedersen-Bjergaard J, Larsen SO. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med 1982; 307: 965-971.
7. Greene MH, Young RC, Merrill JM, De Vita VT. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res 1983; 43: 1891-1898.
8. Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, Landaw SA, Laszlo J, Najean Y, Pisciotta AV, Wasserman LR. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304: 441-447.
9. Boice JD Jr, Greene MH, Killen JY Jr, Ellenberg SS, Keehn RJ, McFadden E, Chen TT, Fraumem JF Jr. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med 1983; 309: 1079-1084.
10. Cuzick J, Erskine S, Edelman D, Calton DA. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. Br J Cancer 1987; 55: 523-529.
11. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, Hansen SW, Hou-Jensen K, Nielsen D, Sigsgaard TC, Specht L, øOsterlind K. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7: 1975-1986.
12. Coleman CN, Williams CJ, Flint A, Glatstein EJ, Rosenberg SA, Kaplan HS. Hematologic neoplasia in patients treated for Hodgkin disease. N Engl J Med 1977; 297: 1249-1252.
13. Pedersen-Bjergaard J, Specht L, Larsen SO, Ersboll J, Struck J, Hansen MM, Hansen HH, Nissen NI. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Lancet 1987; 11: 83-88.
14. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318: 76-81.
15. Rowley JD, Golomb HM, Vardiman J. Nonrandom chromosomal abnormalities in acute nonlymphocytic leukemia in patients treated for Hodgkin disease and non-Hodgkin lymphomas. Blood 1977; 50: 759-770.
16. Pedersen-Bjergaard J, Philip P, Mortensen BT, Ersboll J, Jensen G, Panduro J, Thomsen M. Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. Clinical and cytogenetic characteristics and results of in vitro culture of bone marrow and HLA typing. Blood 1981; 57: 712-723.
17. Rowley JD, Golomb HM, Vardiman JW. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 1981 58: 759-767.
18. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosome No. 5 and 7. J Clin Oncol 1986; 4: 325-345.
19. Johansson B, Mertens F, Heim S, Kristoffersson U, Mitelman F. Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). Eur J Haematol 1991; 47: 17-27.
20. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86: 3542-3552.
21. Hemminki K, Kallama S. Reactions of nitrogen mustards with DNA. 1ARC Scientific Publications 1986; 78: 55-70.
22. Povirk LF, Shuker DE. DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res 1994; 318: 205-226.
23. Pedersen-Bjergard J, Timshel S, Andersen MK, Andersen AS, Philip P. Cytogenetically unrelated clones in therapy-related myelodysplasia and acute myeloid leukemia: experience from the Copenhagen series updated to 180 consecutive cases. Genes Chromosomes Cancer 1998; 23: 337-349.
24. Zhao N, Stoffel A, Wang PW, Eisenhart JD, Espinosa R 3rd, Larson RA, Le Beau MM. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci USA 1997; 94: 6948-6953.
25. Horrigan SK, Arbieva ZH, Xie HY, Kravarusic J, Fulton NC, Naik H, Le TT, Westbrook CA. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q3l. Blood 2000; 95: 2372-2377.
26. Döhner K, Brown J, Hehmann U, Hetzel C, Stewart J, Lowther G, Scholl C, Frohling S, Cuneo A, Tsui LC, Lichter P, Scherer SW, Dohner H. Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. Blood 1998; 92: 4031-4035.
27. Liang H, Fairman J, Claxton DF, Nowell PC, Green ED, Nagarajan L. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: Evidence for multiple critical loci. Proc Natl Acad Sci USA 1998; 95: 3781-3785.
28. Tosi S, Scherer SW, Giudici G, Czepulkowski B, Biondi A, Kearney L. Delineation of multiple deleted regions in 7q in myeloid disorders. Genes Chromosomes Cancer 1999; 25: 384-392.
29. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related MDS and AML after exposure to alkylating agents, and significantly associated with deletion or loss of 5q, a complex karyotype and a poor prognosis. J Clin Oncol 2001; 19: 1405-1413.
30. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002; 99: 1909-1912.
31. Horiike S, Misawa S, Kaneko H, Sasai Y, Kobayashi M, Fujii H, Tanaka S, Yagita M, Abe T, Kashima K, Taniwaki M. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of nos 5 and/or 7 and its possible relationship to replication error phenotype. Leukemia 1999; 13: 1235-1242.
32. Merlat A, Lai JL, Sterkers Y, Demory JL, Bauters F, Preudhomme C, Fenaux P. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia 1999; 13: 250-257.
33. Andersen MK, Pedersen-Bjergaard J. Increased frequency of dicentric chromosomes in therapy-related MDS and AML compared to de novo disease is significantly related to previous treatment with alkylating agents and suggests a specific susceptibility to chromosome breakage at the centromere. Leukemia 2000; 14: 105-111.
34. Andersen MK, Pedersen-Bjergaard J. Multi-color FISH in 54 patients with therapy-related MDS/AML. Blood 2001; 98: 579a (Abstr.).
35. Andersen MK, Christiansen DH, Kirchhoff M, Pedersen-Bjergaard J. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, is closely related to mutation of the tp53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer 2001; 31: 33-41.
36. Bouffler SD, Kemp CJ, Balmain A, Cox R. Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53 - different mice. Cancer Res 1995; 55: 3883-3889.
37. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tisty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 923-935.
38. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937-948.
39. Castro PD, Liang JC, Nagarajan L. Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms. Blood 2000; 95: 2138-2143.
40. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti C, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
41. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-2333.
42. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
43. Fenaux P, Jonveaux P, Quiquandon I, Lai JL, Pignon JM, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP. p53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 1991; 78: 1652-1657.
44. Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P, Wattel E, Fenaux P. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia 1995; 9: 370-381.
45. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, Radich JP. FLT3, RAS and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589-3595.
46. Mitelman F, Brandt L, Nilsson PG. Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings, and bone marrow chromosomes in acute nonlymphocytic leukemia. Blood 1978; 52: 1229-1237.
47. Golomb HM, Alimena G, Rowley JD, Vardiman JW, Testa JR, Sovik C. Correlation of occupation and karyotype in adults with acute nonlymphocytic leukemia. Blood 1982; 60: 404-411.
48. Narod SA, Dubé ID. Occupational history and involvement of chromosomes 5 and 7 in acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1989; 38: 261-269.
49. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974; 251: 437-438.
50. Boultwood J, Lewis S, Wainscoat JS. The 5q- syndrome (review). Blood 1994; 84: 3253-3260.
51. Passmore SJ, Hann IM, Stiller CA, Ramani P, Swansbury GJ, Gibbons B, Reeves BR, Chessells JM. Pediatric myelodysplasia: A study of 68 children and a new prognostic scoring system. Blood 1995; 85: 1742-1750.
52. Hasle H, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U, Fenu S, Fonatsch C, Haas OA, Harbott J, Karclos G, Kerndrup G, Mann G, Niemeyer CM, Ptoszkova H, Ritter J, Slater R, Stary J, Stollmann-Gibbels B, Testi AM, van Wering ER, Zimmermann M. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. Leukemia 1999; 13: 376-385.
53. Ratain MJ, Kaminer LS, Bitran JD, Larson RA, Le Beau MM, Skosey C, Purl S, Hoffman PC, Wade J, Vardiman JW, Daly K, Rowley JD, Golomb HM. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small cell carcinoma of the lung. Blood 1987; 70: 1412-1417.
54. Pui C-H, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, Mirro J Jr, Kalwinsky DK, Dahl GV, Murphy SB. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 1989; 321: 136-142.
55. Pedersen- Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991; 338: 359-363.
56. Tucker MA, Meadows AT, Boice JD Jr, Stovall M, Oberlin O, Stone BJ, Birch J, Voute PA, Hoover RN, Fraumeni JF Jr. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Int 1987; 78: 459-464.
57. Kaldor JM, Day NE, Pettersson F, Clarke EA, Pedersen D, Mehnert W, Bell J, Host H, Prior P, Karjalainen S, Neal F, Koch M, Band P, Choi W, Kirn VP, Arslan A, Zarén B, Belch AR, Storm H, Kittelmann B, Fraser P, Stovall M. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990; 322: 1-6.
58. Pedersen- Bjergaard J, Sigsgaard TC, Nielsen D, Gjedde SB, Philip P, Hansen M, Larsen SO, Rorth M, Mouridsen H, Dombernowsky P. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 1 1 q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol 1992; 10: 1444-1451.
59. Cremin P, Flattery M, McCann SR, Daly PA. Myelodysplasia and acute myeloid leukemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. Ann Oncol 1996; 7: 745-746.
60. Melillo LMA, Sajeva MR, Musto P, Perla G, Cascavilla N, Minervini MM, D'Arena G, Carotenuto M. Acute myeloid leukemia following 3M (mitoxantrone, mitomycin and methotrexate) chemotherapy for advanced breast cancer. Leukemia 1997; 11: 221-2213.
61. Kudo K, Yoshida H, Kiyoi H, Numata S, Horibe K, Naoe T. Etoposide-related acute promyelocytic leukemia. Leukemia 1998; 12: 1171-1175.
62. Carli PM, Sgro C, Parchin-Geneste N, Isambert N, Mugneret F, Girodon F, Maynadie M. Increase therapy-related leukemia secondary to breast cancer. Leukemia 2000; 14: 1014-1017.
63. Xue Y, Lu D, Guo Y, Lin B. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leukemia Res 1992; 16: 1113-1123.
64. Pedersen- Bjergaard J, Philip P. Balanced translocations involving chromosome bands 11 q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 1991; 78: 1147-1148.
65. Larson RA, Le Beau MM, Ratain MJ, Rowley JD. Balanced translocations involving chromosome bands 11 q23 and 21q22 in therapy-related leukemia. Blood 1992; 79: 1892-1893.
66. Pedersen-Bjergaard J, Andersen MK, Johansson B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol 1998; 16: 1897-1898.
67. Secker-Walker LM, Moorman AV, Bain BJ, Mehta AB. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. Leukemia 1998; 12: 840-844.
68. Dissing M, Le Beau MM, Pedersen- Bjergaard J. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? J Clin Oncol 1998; 16: 1890-1896.
69. Detourmignies L, Castaigne S, Stoppa AM, Harousseau JL, Sadoun A, Janvier M, Demory JL, Sanz M, Berger R, Bauters F, Chomienne C, Fenaux P. Therapy-related acute promyelocytic leukemia: a report on 16 cases. J Clin Oncol 1992; 10: 1430-1435.
70. Look TA. Oncogenic transcription factors in human leukemia. Science 1997; 278: 1059-1064.
71. Strout MP, Caligiuri MA. Developments in cytogenetics and oncogenes in acute leukemia. Curr Opin Oncol 1997; 9: 8-17.
72. Rowley JD. The role of chromosome translocations in leukemo-genesis. Semin Hematol 1999; 36 (Suppl. 7): 59-72.
73. Felix CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 2001; 36: 525-535.
74. Earnshaw WC, Halligan B, Cooke CA, Heck MM, Liu LF. Topoisomerase II is a structural component of mitotic chromosome scaffolds. J Cell Biol 1985; 100: 1706-1715.
75. Richardson C, Jasin M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature 2000; 405: 697-700.
76. Zechiedrich EL, Osheroff N. Eukaryotic topoisomerase recognize nucleic acid topology by preferentially interacting with DNA crossovers. EMBO J 1990; 13: 4555-4562.
77. Sperry AO, Blasquez VC, Garrard WT. Dysfunction of chromosomal loop attachment sites: Illegitimate recombination linked to matrix association regions and topoisomerase II. Proc Natl Acad Sci USA 1989; 86: 5497-5501.
78. Lui LF. DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 1989; 58: 351-375.
79. Pommier Y, Kohn K. Topoisomerase II inhibition by antitumor intercalators and demethylepipoclophyllotoxins. in: Glazer RI (ed.). Development in Cancer Chemotherapy. CRC: Boca Raton, FL, 1989, p 175.
80. Chen C-L, Fuscoe JC, Liu Q, Relling MV. Etoposide causes illegitimate V(D)J recombination in human lymphoid leukemic cells. Blood 1996; 88: 2210-2218.
81. Aplan PD, Chervinsky DS, Stanulla M, Burhans WC. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Blood 1996; 87: 2649-2658.
82. Stanulla M, Wang J, Chervinsky DS, Aplan PD. Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus. Leukemia 1997; 11: 490-496.
83. Felix CA, Lange BJ, Hosler MR, Fertala J, Bjornsti MA. Chromosome band 1 1 q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res 1995; 55: 4287-4292.
84. Strissel PL, Strick R, Rowley JD, Zeleznik-Le NJ. An in vivo topopisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Blood 1998; 92: 3793-3803.
85. Ahuja HG, Felix CA, Aplan P. Potential role for DNA topoisomerase II poisons in the generation of t(11,20)(p15;q1 I) translocations. Genes Chromosomes Cancer 2000; 29: 96-105.
86. Pui C-H, Relling, MV, Rivera GK, Hancock ML, Raimondi SC, Heslop HE, Santana VM, Ribeiro RC, Sandlund JT, Mahmoud HH, Evans WE, Crist WM, Krance RA. Epipoclophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia, 1995; 9: 1990-1996.
87. Ross JA, Potter JD, Reaman GH, Pendergrass TW, Robison LL. Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): a report from the Children's Cancer Group. Cancer Causes Control 1996; 7: 581-590.
88. Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci USA 2000; 97: 4790-4795.
89. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002; 1: 63-74.
90. Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T, Takenaka K, Mizuno S, Condo H, Okamura T, Dohy H, Niho Y. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996; 87: 4789-4796.
91. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-1918.
92. Horiike S, Yokota S, Nakao M, Iwai T, Sasai Y, Kaneko H, Taniwaki M Kashima K, Fujii H, Abe T, Misawa S. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 1997; 11: 1442-1446.
93. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, Sonoda Y, Abe T, Kahsima K, Matsuo Y, Naoe T. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997; 11: 1605-1609.
94. Schnittger S, Schoch C, Kern W, Staib P, Wuchter C, Sauerland MC, Serve H, Buechner T, Haferlach T, Hiddemann W. FLT3 length mutations in AML correlation to cytogenetics, FAB-subtype and prognosis in 652 patients. Blood 2000; 96 (Suppl. 1): 826a (Abstr.).
95. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
96. Caligiuri MA, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F, Knuutila S, Mrozek K, Oberkircher AR, Marcucci G, de la Chapelle A, Elonen E, Block AW, Rao PN, Herzig GP, Powell BL, Ruutu T, Schiffer CA, Bloomfield CD. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 1998; 58: 55-59.
97. Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D, Haferlach T, Buchner T, Wormann B, Hiddemann W, Griesinger F. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavourable subset of AML. Leukemia 2000; 14: 798-804.
98. Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA, Bloomfield CD, de la Chapelle A, Krahe R. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci USA 2001; 98: 1124-1129.
99. Christiansen DH, Pedersen-Bjergaard J. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy. Leukemia 2001; 15: 1848-1851.
100. Albin M, Björk J, Welinder H, Tinnerberg H, Mauritzson N, Johansson B, Billstrom R, Stromberg U, Mikoczy Z, Ahlgren T, Nilsson PG, Mitelman F, Hagmar L. Acute myeloid leukemia and clonal chromosome aberrations in relation to past exposure to organic solvents. Scand J Work Environ Health 2000; 26: 482-491.
101. Pedersen- Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 1990; 76: 1083-1091.
102. Boice JD Jr, Day NE, Andersen A, Brinton LA, Brown R, Choi NW, Clarke EA, Coleman MP, Curtis RE, Flannery JT, Hakama M, Hakulinen T, Howe GR, Jensen OM, Kleinerman RA, Magnin D, Magnus K, Makela K, Malker B, Miller AB, Nelson N, Patterson CC, Pettersson F, Pompe-Kirn V, Primic-Zakelj M, Prior P, Ravnihar B, Skeet RG, Skjerven JE, Smith PG, Sok M, Spengler RF, Storm HH, Stovall M, Tomkins GWO, Wall C. Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst 1985; 74: 955-975.
103. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326: 1745-1751.
104. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Holowaty E, Karjalainen S, Langmark F, Nasca PC, Schwartz AG, Schymura MJ, Storm HH, Toogood P, Weyer P, Moloney WC. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. J Natl Cancer Inst 1994; 86: 1315-1324.
105. Gundestrup M, Andersen MK, Sveinbjornsdottir E, Rafnsson V, Storm HH, Pedersen-Bjergaard J. Cytogenetics of myelodysplasia and acute myeloid leukaemia in aircrew and people treated with radiotherapy. Lancet 2000; 256: 2158.
106. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations in cancer (2000). http://cgap.nci.nih.gov/Chromosomes/Mitelman (accessed on Jan 23, 2001).
107. Farber E. Chemical carcinogenesis. N Engl J Med 1981; 305: 1379-1389.
108. Vigliani EC, Saita G. Benzene and leukemia. N Engl J Med 1964; 271: 872-876.
109. Infante PF, Rinsky RA, Wagoner JK, Young RJ. Leukaemia in benzene workers. Lancet 1977; 2: 76-78.
110. Aksoy M, Erdem S. Follow-up study on the mortality and the development of leukemia in 44 pancytopenic patients with chronic exposure to benzene. Blood 1978; 52: 285-292.
111. Rinsky RA, Smith AB, Hornung R, Filloon TG, Young RJ, Okun AH, Landrigan PJ. Benzene and leukemia an epidemiologic risk assessment. N Engl J Med 1987; 316: 1044-1050.
112. Kinlen LJ, Rogot E. Leukaemia and smoking habits amoung United States veterans. Br Med J 1988; 297: 657-659.
113. McLaughlin JK. Cigarette smoking and leukemia. J Natl Cancer Inst 1989; 81: 1262-1263.
114. Garfinkel L, Boffetta P. Association between smoking and leukemia in two American Cancer Society prospective studies. Cancer 1990; 65: 2356-2360.
115. Alexander FE, Patheal SL, Biondi A, Brandalise S, Cabrera ME, Chan LC, Chen Z, Cimino G, Cordoba JC, Gu LJ, Hussein H, Ishii E, Kamel AM, Labra S, Magalhaes IQ, Mizutani S, Petridou E, de Oliveira MP, Yuen P, Wiemels JL, Greaves MF. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res 2001; 61: 2542-2546.
116. McDonald TA, Holland NT, Skibola C, Duramad P, Smith MT. Hypothesis: phenol and hydroquinone derived mainly from diet and gastrointestinal flora activity are causal factors in leukemia. Leukemia 2001; 15: 10-20.